Clinical use of cerebral oximetry in extremely preterm infants is feasible

Simon Hyttel-Sørensen, Topun Austin, Frank van Bel, Manon Benders, Olivier Claris, Eugene M Dempsey, Monica Fumagalli, Christian Gluud, Cornelia Hagmann, Lena Hellström-Westas, Petra Lemmers, Gunnar Naulaers, Wim van Oeveren, Adelina Pellicer, Gerhard Pichler, Claudia Roll, Lina Saem Støy, Martin Wolf, Gorm Greisen

33 Citationer (Scopus)

Abstract

The research programme Safeguarding the Brains of our smallest Children (SafeBoosC) aims to test the benefits and harms of cerebral near-infrared spectroscopy (NIRS) oximetry in infants born before 28 weeks of gestation. In a phase II trial, infants will be randomised to visible cerebral NIRS oximetry with pre-specified treatment guidelines compared to standard care with blinded NIRS-monitoring. The primary outcome is duration multiplied with the extent outside the normal range of regional tissue oxygen saturation of haemoglobin (rStO2) of 55 to 85% in percentage hours (burden). This study was a pilot of the Visible -Oximetry Group.
OriginalsprogEngelsk
TidsskriftDanish Medical Journal
Vol/bind60
Udgave nummer1
Sider (fra-til)A4533
StatusUdgivet - 2013

Fingeraftryk

Dyk ned i forskningsemnerne om 'Clinical use of cerebral oximetry in extremely preterm infants is feasible'. Sammen danner de et unikt fingeraftryk.

Citationsformater